AEON Biopharma (NASDAQ:AEON) Rating Reiterated by HC Wainwright

by · The Cerbat Gem

HC Wainwright reissued their buy rating on shares of AEON Biopharma (NASDAQ:AEON – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a $5.00 price target on the stock.

AEON Biopharma Trading Down 2.7 %

Shares of AEON stock opened at $1.10 on Tuesday. AEON Biopharma has a 12 month low of $0.64 and a 12 month high of $17.17. The business’s 50 day moving average is $1.03 and its two-hundred day moving average is $2.92.

AEON Biopharma (NASDAQ:AEON – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. As a group, research analysts forecast that AEON Biopharma will post -0.77 EPS for the current year.

Institutional Trading of AEON Biopharma

An institutional investor recently raised its position in AEON Biopharma stock. Vanguard Group Inc. increased its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 261.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 758,992 shares of the company’s stock after buying an additional 549,207 shares during the quarter. Vanguard Group Inc. owned 2.01% of AEON Biopharma worth $8,804,000 at the end of the most recent reporting period. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

(Get Free Report)

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.

See Also